Dyne Therapeutics is focused on delivering functional improvement for people living with genetically driven neuromuscular diseases. We are developing therapeutics that target muscle and the central nervous system (CNS) to address the root cause of disease. The company is advancing clinical programs for myotonic dystrophy type 1 (DM1) and Duchenne muscular dystrophy (DMD), and preclinical programs for facioscapulohumeral muscular dystrophy (FSHD) and Pompe disease. At Dyne, we are on a mission to deliver functional improvement for individuals, families and communities. Learn more https://www.dyne-tx.com/.
To view our community guidelines, click here: https://bit.ly/3BYPnpK
Company Details
- Employees
- 227
- Founded
- -
- Address
- 1560 Trapelo Rd, Waltham,massachusetts 02451,united States
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- dyne-tx.com
- Keywords
- Technician jobs.
- HQ
- Waltham, Massachusetts
Dyne Therapeutics Questions
Dyne Therapeutics's website is dyne-tx.com
Dyne Therapeutics's LinkedIn profile is https://www.linkedin.com/company/dynetx
Dyne Therapeutics has
227 employees.
View email and phone details for 227
employees at Dyne Therapeutics.
Dyne Therapeutics's industry is
Biotechnology Research
Dyne Therapeutics's top competitors are
Verve Therapeutics,
Sarepta Therapeutics,
Beam Therapeutics,
Kymera Therapeutics,
Entrada Therapeutics,
Vertex Pharmaceuticals,
Tessera Therapeutics,
Avidity Biosciences, Inc.,
Alnylam Pharmaceuticals,
Stoke Therapeutics.
Dyne Therapeutics's categories are Biotechnology Research
Dyne Therapeutics's founding year is 2018
